Gastrointestinal Drugs Market Research Report- Forecast till 2027

Gastrointestinal Drugs Market Research Report: Information by Drug Class (Acid Neutralizers, Anti-Inflammatory Drugs, Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Biologics and others), Route of Administration (Oral, Parenteral and Rectal), Application (Inflammatory Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, Gastroenteritis and others), Distribution Channel (Retail Pharmacies, Online Pharmacies and Hospital Pharmacies) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0115-HCR | February 2021 | Region: Global | 90 pages

Gastrointestinal Drugs Market Overview


Gastrointestinal drug as the name suggests is used to treat gastrointestinal problems prevailing almost all across the globe. An increasing geriatric population leads to more gastrointestinal problems. Also, the changing lifestyle is the main reason that drives the gastrointestinal problem in many regions. The increasing investment done by governments of various nations in the field of life science and the health care sector increases the market size of the gastrointestinal drugs market. Additionally, the increasing number of patients suffering from gastrointestinal problems is another major growth driving factor.


The market for gastrointestinal drugs is expected to grow at a higher CAGR of 4.9 in the global market to account for a higher market value of approximately USD 59,300 million by the end of the forecasted period from 2017-2023.


COVID 19 Analysis


The global pandemic of COVID 19 has affected a large section of society. Most of the people who had got Corona Virus is struggling with gastric issues. Owing to the increasing cases of gastric diseases, huge investments have been made by manufacturers for the development of gastrointestinal treatment. This investment gives rise to increasing medication demand and hence increase the gastrointestinal drugs market size in the global market.


The global pandemic of COVID 19 has a positive effect on the global gastrointestinal drugs market share of this drug. The market share for this drug is also expected to grow furthermore in the coming years.


Market Dynamics


Drivers


The increasing number of gastrointestinal diseases among old age people is one of the major driving factors. Increasing investment by governments of various countries in the field of life science and the healthcare sector accelerates the growth rate. Various trials conducted by various pharmaceutical companies drive the market in the global gastrointestinal drugs market. Increasing the introduction of products recently also drives the market.


Opportunities


The gastrointestinal drugs market is growing tremendously in the global market. High investment done by the various practitioners and pharmaceutical companies provides growth opportunities during the forecasted period. Newly launched drugs help in providing relief from bowel syndrome present especially in patients suffering from constipation. High research and development in the pharmaceutical industry will provide various growth opportunities at the end of the gastrointestinal drugs market forecasted period.


Restraints


Though there are various driving factors and growth opportunities available in the global gastrointestinal drugs market but some factors restraint its growth. The high cost of raw material used in manufacturer gastrointestinal drugs is the major factor that hampers its growth. Also, the increasing presence of the counterfeit drug is another factor that restricts its growth. The high amount of expenditure on research and development also restrain the gastrointestinal drugs market growth.


Value Chain Analysis


The gastrointestinal drugs market is growing rapidly in the global market owing to various benefits provided by it. It helps in providing relief during the pain caused by gastric diseases. There are various types of gastric drugs namely antidiarrheal drugs, antinauseants and laxatives, anti-inflammatory drugs, biologics, acid neutralizers, biologics, and many others available in the gastrointestinal drugs market. This drug also helps in treating various other stomach-related issues. This drug does not have worse side effects and can be consumed by teenagers as well.


Regional Market Summary


Gastrointestinal Drugs global Market Share (%), by Region, 2018  Gastrointestinal Drugs Market


Sources: MRFR Analysis


Market Segmentation


The gastrointestinal drugs market has been divided all across the globe based on the drug class, application, route of administration, and distribution channel.


Based on the Drug Class


The market for gastrointestinal drugs has been divided all across the globe based on the drug class into antiemetic and antinauseants, antidiarrheal and laxatives, anti-inflammatory drugs, biologics, acid neutralizers, and many others. The acid neutralizer is further sub-divided into proton pump inhibitors, H2 antagonists, and antacids.


Based on the Application


The market for gastrointestinal drugs has been divided all across the globe based on the application into gastroenteritis, celiac disease, Crohn’s disease, irritable bowel syndrome, inflammatory ulcerative Colitis, and many others.


Based on the Route of Administration


The market for gastrointestinal drugs has been divided all across the globe based on the route of administration into rectal, parenteral, and oral.


Based on the Distribution Channel


The market for gastrointestinal drugs has been divided all across the globe based on the distribution channel into hospital pharmacies, online pharmacies, and retail pharmacies.


Regional Analysis


The market has been divided all across the globe based on the region into the American region, European region, Asia-Pacific region, and the Middle East and African region. The largest market in the global market is held by the American region owing to increasing healthcare expenditure coupled with increasing digestive disorders. The presence of a well-established healthcare sector is another driving factor in this region.


The second-largest market share in the global gastrointestinal drugs market is held by the European region owing to increasing investment in the healthcare industry coupled with increasing awareness regarding digestive diseases and treatment. Increasing demand for the most efficient and effective treatment is another driving factor in this region.


The third-largest market share in the global gastrointestinal drugs market is held by the Asia-Pacific region owing to the presence of highly populated countries like China and India. An increasing number of patients, a rising geriatric population, and rising investments initiatives taken by the government for healthcare facilities drive the growth in the Asia-Pacific region.


The least growth was observed in the Middle East and African region owing to low healthcare infrastructure, and low economic development in this region. Poor health facilities also restrict growth, especially in the African region.


Competitive Landscape


The most prominent major key players in the gastrointestinal drugs global market all across the globe are mentioned below:



  • Takeda Pharmaceuticals

  • Allergan Plc

  • Novo Nordisk A/S

  • AstraZeneca Plc

  • AbbVie Inc.

  • Valeant Pharmaceuticals Inc.

  • Johnson and Johnson

  • Bayer AG

  • Boehringer Ingelheim GmbH

  • GlaxoSmithKline Plc.

  • Jansssen Biotech Inc.

  • Sanofi


These major key players use various strategies to sustain gastrointestinal drugs market position in the gastrointestinal drugs market in the global market by going for mergers, and acquisitions, by collaborating, setting up a new joint venture, establishing a partnership, developing a new production process, developing a new product line, innovation in the existing product, and many others to expand their customer base in the untapped market of the gastrointestinal drug all across the globe.


Recent Developments



  • In November 2018, Tenapanor drug has received acceptance from New Drug Application (NDA), and FDA by Ardelyx. This drug is a sodium transporter NHE3 that helps in treating constipation.

  • In June 2019, an oral sodium transporter NHE3 inhibitor has been filed with NDS by Knight Therapeutics Inc. It helps in treating irritable bowel syndrome for Canadian patients.

  • In March 2020, approval was granted for Pizensy (lactitol) from the United States Food and Drug Administration (FDA) by Sebela Pharmaceuticals. This drug will help in treating (CIC) chronic idiopathic constipation prevailing commonly in adults.

  • In March 2021, a phase III clinical trial was initiated by Janssen Research and Development, LLC to evaluate the safety of ustekinumab. This trial will help in treating Crohn’s disease in pediatric patients ranging from moderate level to severe levels.

  • Johnson and Johnson are spending a huge amount of money on research and development which will help the company to sustain its global gastrointestinal drugs market position. This will also help in getting an upper edge over its competitors.


Report Overview


This global gastrointestinal drugs market research report consists of the following elements mentioned below:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This market research report contains factors that drive the growth of the gastrointestinal drugs market in the global market along with the factors that restrict its growth in the global market. The opportunities available for growth during the forecasted period are mentioned. The impact of COVID 19 on the sales revenue of the gastrointestinal drugs market all across the globe is mentioned. The future growth rate during the forecasted period is estimated and mentioned.


Intended Audience


Biotechnology companies, government organizations, healthcare organizations, healthcare providers, research and development (R & D) companies, gastrointestinal drugs manufacturing companies, and many others.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 59,300 Million
  • 2027: Significant Value
  •   CAGR   4.9% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drug Class, Route of Administration, Application and Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi
      Key Market Opportunities   high raw material costs and growing presence of counterfeit drugs
      Key Market Drivers

  • increasing prevalence of gastrointestinal diseases
  • rising investments and funding in the field of life science research


  • Frequently Asked Questions (FAQ) :


    Gastrointestinal drugs market valuation can touch USD 59,300 million by 2025.

    Gastrointestinal drugs market is expected to exhibit a CAGR of 4.9% from 2019 to 2025.

    Gastrointestinal drugs market is driven by the alarming cases of GI among the masses.

    Presence of counterfeit drugs and high raw material costs can restrain the global gastrointestinal drugs market growth.

    GlaxoSmithKline Plc., Janssen Biotech Inc., Johnson & Johnson, Valeant Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Takeda Pharmaceuticals, Allergan Plc, Bayer AG, Sanofi, AstraZeneca Plc, Novo Nordisk A/S, and AbbVie Inc. are major players of the global gastrointestinal drugs market.

    Table of Contents:

    Chapter 1. Executive Summary

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Overview

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.2.1 R&D and Designing

    5.2.2 Manufacturing

    5.2.3 Distribution & Sales

    5.2.4 Post-Sales Review

    Chapter 6. Global Gastrointestinal Drugs Market, by Drug Class

    6.1 Overview

    6.2 Acid Neutralizers

    6.2.1 Antacids

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2 H2 Antagonists

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.3 Proton Pump Inhibitors

    6.3 Anti-Inflammatory Drugs

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Antidiarrheal and Laxatives

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Antiemetic and Antinauseants

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6 Biologics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.7 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7. Global Gastrointestinal Drugs Market, by Route of Administration

    7.1 Overview

    7.2 Oral

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Parenteral

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Rectal

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Gastrointestinal Drugs Market, by Application

    8.1 Overview

    8.2 Inflammatory Ulcerative Colitis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Irritable Bowel Syndrome

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Crohn's Disease

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.5 Celiac Disease

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.6 Gastroenteritis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.7 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 9. Global Gastrointestinal Drugs Market, by Distribution Channel

    9.1 Overview

    9.2 Retail Pharmacies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.3 Retail Pharmacies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.4 Hospital Pharmacies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Gastrointestinal Drugs Market, by Region

    10.1 Overview

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Overview

    11.2 Competitive Analysis

    Chapter 12. Company Profile

    12.1 Takeda Pharmaceticals

    12.1.1 Company Overview

    12.1.2 Products/Services Offered

    12.1.3 Financial Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.1.6 Key Strategies

    12.2 Allergan Plc

    12.2.1 Company Overview

    12.2.2 Products/Services Offered

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.2.6 Key Strategies

    12.3 Novo Nordisk A/S

    12.3.1 Company Overview

    12.3.2 Products/Services Offered

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.3.6 Key Strategies

    12.4 AstraZeneca Plc

    12.4.1 Company Overview

    12.4.2 Products/Services Offered

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.4.6 Key Strategies

    12.5 AbbVie Inc.

    12.5.1 Company Overview

    12.5.2 Products/Services Offered

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.5.6 Key Strategies

    12.6 Valeant Pharmaceuticals Inc.

    12.6.1 Company Overview

    12.6.2 Products/Services Offered

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.6.6 Key Strategies

    12.7 Johnson & Johnson

    12.7.1 Overview

    12.7.2 Products/Services Offered

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.7.6 Key Strategies

    12.8 Bayer AG

    12.8.1 Overview

    12.8.2 Products/Services Offered

    12.8.3 Financial Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.8.6 Key Strategies

    12.9 Boehringer Ingelheim GmbH

    12.9.1 Overview

    12.9.2 Products/Services Offered

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.9.6 Key Strategies

    12.10 GlaxoSmithKline Plc.

    12.10.1 Overview

    12.10.2 Products/Services Offered

    12.10.3 Financial Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.10.6 Key Strategies

    12.11 Janssen Biotech Inc.

    12.11.1 Overview

    12.11.2 Products/Services Offered

    12.11.3 Financial Overview

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.11.6 Key Strategies

    12.12 Sanofi

    12.12.1 Overview

    12.12.2 Products/Services Offered

    12.12.3 Financial Overview

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.12.6 Key Strategies

    12.13 Others

    Chapter 12 Appendix

    12.1 References

    12.2 Related Reports


    LIST OF TABLES

    Table 1 Global Gastrointestinal Drugs Market Synopsis, 2020-2027

    Table 2 Global Gastrointestinal Drugs Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 4 Global Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 5 Global Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 6 Global Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 7 Global Gastrointestinal Drugs Market, by Region, 2020-2027 (USD Million)

    Table 8 Americas: Gastrointestinal Drugs Market, by Region, 2020 and 2025

    Table 9 Americas: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 10 Americas: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 11 Americas: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 12 Americas: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 13 North America: Gastrointestinal Drugs Market, by Country, 2020-2027 (USD Million)

    Table 14 North America: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 15 North America: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 16 North America: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 17 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 18 US: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 19 US: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 20 US: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 21 US: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 22 Canada: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 23 Canada: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 24 Canada: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 25 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 26 Latin America: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 27 Latin America: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 28 Latin America: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 29 Latin America: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 30 Europe: Gastrointestinal Drugs Market, by Region, 2020-2027 (USD Million)

    Table 31 Europe: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 32 Europe: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 33 Europe: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 34 Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 35 Western Europe: Gastrointestinal Drugs Market, by Country, 2020-2027 (USD Million)

    Table 36 Western Europe: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 37 Western Europe: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 38 Western Europe: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 39 Western Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 40 Eastern Europe: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 41 Eastern Europe: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 42 Eastern Europe: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 43 Eastern Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 44 Asia-Pacific: Gastrointestinal Drugs Market, by Country, 2020-2027 (USD Million)

    Table 45 Asia-Pacific: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 46 Asia-Pacific: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 47 Asia-Pacific: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 48 Asia-Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 49 Middle East & Africa: Gastrointestinal Drugs Market, by Region, 2020-2027 (USD Million)

    Table 50 Middle East & Africa: Gastrointestinal Drugs Market, by Drug Class, 2020-2027 (USD Million)

    Table 51 Middle East & Africa: Gastrointestinal Drugs Market, by Route of Administration, 2020-2027 (USD Million)

    Table 52 Middle East & Africa: Gastrointestinal Drugs Market, by Application, 2020-2027 (USD Million)

    Table 53 Middle East & Africa: Gastrointestinal Drugs Market, by Distribution Channel, 2020-2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Market Structure of the Global Gastrointestinal Drugs Market

    Figure 3 Market Dynamics of the Global Gastrointestinal Drugs Market

    Figure 4 Global Gastrointestinal Drugs Market Share, by Drug Class, 2020 (%)

    Figure 5 Global Gastrointestinal Drugs Market Share, by Drug Class, 2020 (USD Million)

    Figure 6 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2020 (%)

    Figure 7 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2020 (USD Million)

    Figure 8 Global Gastrointestinal Drugs Market Share, by Application, 2020 (%)

    Figure 9 Global Gastrointestinal Drugs Market Share, by Application, 2020 (USD Million)

    Figure 10 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2020 (%)

    Figure 11 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2020 (USD Million)

    Figure 12 Global Gastrointestinal Drugs Market Share, by Region, 2020 (%)

    Figure 13 Americas: Gastrointestinal Drugs Market Share, by Region, 2020 (%)

    Figure 14 North America: Gastrointestinal Drugs Market Share, by Country, 2020 (%)

    Figure 15 Europe: Gastrointestinal Drugs Market Share, by Region, 2020 (%)

    Figure 16 Western Europe: Gastrointestinal Drugs Market Share, by Country, 2020 (%)

    Figure 17 Asia-Pacific: Gastrointestinal Drugs Market Share, by Country, 2020 (%)

    Figure 18 Middle East & Africa: Gastrointestinal Drugs Market Share, by Region, 2020 (%)

    Figure 19 Global Gastrointestinal Drugs Market: Company Share Analysis, 2020 (%)

    Figure 20 Takeda Pharmaceuticals: Key Financials

    Figure 21 Takeda Pharmaceuticals: Segmental Revenue

    Figure 22 Taked a Pharmaceuticals: Regional Revenue

    Figure 23 Allergan Plc: Key Financials

    Figure 24 Allergan Plc: Segmental Revenue

    Figure 25 Allergan Plc: Regional Revenue

    Figure 26 Novo Nordisk A/S: Key Financials

    Figure 27 Novo Nordisk A/S: Segmental Revenue

    Figure 28 Novo Nordisk A/S: Regional Revenue

    Figure 29 AstraZeneca Plc: Key Financials

    Figure 30 AstraZeneca Plc: Segmental Revenue

    Figure 31 AstraZeneca Plc: Regional Revenue

    Figure 32 AbbVie Inc.: Key Financials

    Figure 33 AbbVie Inc.: Segmental Revenue

    Figure 34 AbbVie Inc.: Regional Revenue

    Figure 35 Valeant Pharmaceuticals Inc.: Key Financials

    Figure 36 Valeant Pharmaceuticals Inc.: Segmental Revenue

    Figure 37 Valeant Pharmaceuticals Inc.: Regional Revenue

    Figure 38 Johnson & Johnson: Key Financials

    Figure 39 Johnson & Johnson: Segmental Revenue

    Figure 40 Johnson & Johnson: Regional Revenue

    Figure 41 Bayer AG: Key Financials

    Figure 42 Bayer AG: Segmental Revenue

    Figure 43 Bayer AG: Regional Revenue

    Figure 44 Boehringer Ingelheim GmbH: Key Financials

    Figure 45 Boehringer Ingelheim GmbH: Segmental Revenue

    Figure 46 Boehringer Ingelheim GmbH: Regional Revenue

    Figure 47 GlaxoSmithKline Plc.: Key Financials

    Figure 48 GlaxoSmithKline Plc.: Segmental Revenue

    Figure 49 GlaxoSmithKline Plc.: Regional Revenue

    Figure 50 Janssen Biotech Inc.: Key Financials

    Figure 51 Janssen Biotech Inc.: Segmental Revenue

    Figure 52 Janssen Biotech Inc.: Regional Revenue

    Figure 53 Sanofi: Key Financials

    Figure 54 Sanofi: Segmental Revenue

    Figure 55 Sanofi: Regional Revenue